Navigation Links
AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
Date:8/29/2012

livery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.   AcelRx plans to initiate a Phase 2 study, pending protocol approval, for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' patent portfolio, including the useful life of its U.S. patents and the European patent, the continued expansion of its patent protection, market exclusivity, its ability to protect its proprietary technology, the scope of patent protection, and issued and planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the execution of the Phase 3 clinical studies for ARX-01,  the initiation of Phase 2 clinical trial for ARX-04, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and c
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , August 28, 2015 The scientific ... collaboration with one of the leading academics in the field ... world record holder in life extension for model animals - ... biology of aging and age-related diseases, primarily, around the stability ... has just been published as "Stability analysis of a model ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... LOUISVILLE, Ky., Nov. 20 The National Association ... in the war on methamphetamine. The National Precursor Log ... purchase limitations on over-the-counter (OTC) medicines containing pseudoephedrine in real-time ... is based on a system that was developed and tested ...
... , ... 20 Reportlinker.com announces that a new ... catalogue. , Global Self Monitoring Blood ... Growth , http://www.reportlinker.com/p0164657/Global-Self-Monitoring-Blood-Glucose-Market-(SMBG )-Increasing-Adoption-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ...
Cached Medicine Technology:National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 2National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 3Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 2Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 3Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 4Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 5Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 6Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 7Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth 8
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... abuse, or those who might personally be struggling with chemical dependency, may be ... from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, ... all for a good cause. In its second year, the “Music With A Mission” ... Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to ...
(Date:8/28/2015)... ... 28, 2015 , ... The newest therapy to receive orphan drug status for ... time soon, according to educational website Surviving Mesothelioma. Click here to read their ... for mesothelioma last week from the FDA, will now head into Phase I clinical ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... Dec. 1 MassMutual Retirement Services Division has added ... Nonprofit activity has more than tripled in 2008 compared ... Dan Darby joined MassMutual on December 1 ... reports to M. Palmer Whitney, national managing director, nonprofit ...
... 1 The Food Allergy & Anaphylaxis Network (FAAN) ... CEO, replacing Founder Anne Munoz-Furlong, who is retiring. , ... to FAAN extensive knowledge of anaphylaxis, a severe, potentially ... Senior Director of Marketing, she led the marketing team ...
... supplements can also trigger acute organ failure, study says ... the single largest class of drugs that cause idiosyncratic ... accounts for about 13 percent of cases of acute ... most common cause of death from acute liver failure. ...
... Dry-needling, steroids effective against plantar fasciitis, researchers say ... researchers say they,ve developed a fast, effective, non-invasive ... plantar fasciitis. , Using a combination of "dry-needling" ... say their approach achieved a 95 percent success ...
... as one in five of all Americans who survive a ... emotionally paralyzed survivors of 9/11 and broken up survivors, families. ... lower the chance of developing the disorder, but thanks to ... PTSD may be just around the corner. , Prof. Joseph ...
... will die of AIDS. In fact, nearly 7,000 people die each day ... 1 is World AIDS Day, a day of awareness and outreach to help ... Day 2008 is You Can Make a Difference and ... as well as helping dispel the myths and misconceptions about HIV. , ...
Cached Medicine News:Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:FAAN Names New CEO 2Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:Easing the stress of trauma 2Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
Medicine Products: